Oncology Central

PGE inhibitor demonstrates promising activity in Phase I study

A multi-institutional group of researchers have presented initial clinical results from a first-in-human study of E7046 in patients with cancers having high-myeloid cell infiltration. The findings were presented recently at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium (25–27 January, CA, USA).

E7046 is a potent, highly selective small-molecule inhibitor of PGE2-receptor type 4. Preclinical data have demonstrated that it reverses PGE2-mediated tumor immune suppression.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.